A phase 2 randomized trial (KEYNOTE-022 [A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma]) enrolled 120 patients with BRAF-mutated melanoma (largely stage IV) to compare the efficacy of the combination of pembrolizumab, dabrafenib and trametinib versus dabrafenib, trametinib plus placebo.88 Here, BRAF is linked to melanoma.